Changes in bone mineral density during therapy in childhood acute lymphoblastic leukemia.
Quantitative computed tomography was performed to determine bone mineral density (BMD) at initial presentation and following 6-months of therapy in children with acute lymphoblastic leukemia (ALL). Of 46 children enrolled, the complete set of observations was available in 32. The combined mean BMD of three lumbar vertebrae at diagnosis and during treatment were 167.1+/-27.4 and 148.8+/-31.4 mg/ cm3, respectively (P=0.001). Twenty six children (81.2%) had a decrease in BMD on treatment. The mean BMD for each of 3 vertebrae declined as well. The mean T-scores at diagnosis and during therapy were -0.15+/-0.9 and -0.86+/-1.0, respectively (P=0.001). Conventional radiographs revealed metaphyseal lucencies which were replaced with metaphyseal dense bands with therapy. To conclude, there was a significant reduction of BMD in children with ALL following 6- months of treatment.
Kaushik
Ashlesha
A
Pediatric Hematology Oncology Unit, Advanced Pediatrics Center and Department of Radiodiagnosis and Imaging, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Bansal
Deepak
D
Khandelwal
N
N
Trehan
Amita
A
Marwaha
R K
RK
D015502:Absorptiometry, Photon; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects* / Q000528:radiation effects; D002675:Child, Preschool; D003907:Dexamethasone / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy*; D011241:Prednisone / Q000008:administration & dosage; D011446:Prospective Studies; D014057:Tomography, X-Ray Computed; D014750:Vincristine / Q000008:administration & dosage
D018931:Antineoplastic Agents, Hormonal; D000972:Antineoplastic Agents, Phytogenic; D014750:Vincristine; D003907:Dexamethasone; D011241:Prednisone